The Natural Compound N-butylidenephthalide Derived from Angelica Sinensis Inhibits Malignant Brain Tumor Growth in Vitro and in Vivo.
From: Department of Applied Life Science, Asia University, Taichung, Taiwan.
Journal of neurochemistry
- Publish Date: Nov 2006
- ISSN: 0022-3042
- Volume: 99
- Issue: 4
- Pages: 1251-62
- Medium: Print
- Language: English
- Citation (JAMA): Tsai Nu-Man, Chen Yi-Lin, Lee Chau-Chin, et al. The Natural Compound N-butylidenephthalide Derived from Angelica Sinensis Inhibits Malignant Brain Tumor Growth in Vitro and in Vivo.. J. Neurochem. Nov 2006;99:1251-62
Abstract
The naturally-occurring compound, n-butylidenephthalide (BP), which is isolated from the chloroform extract of Angelica sinensis (AS-C), has been investigated with respect to the treatment of angina. In this study, we have examined the anti-tumor effects of n-butylidenephthalide on glioblastoma multiforme (GBM) brain tumors both in vitro and in vivo. In vitro, GBM cells were treated with BP, and the effects of proliferation, cell cycle and apoptosis were determined. In vivo, DBTRG-05MG, the human GBM tumor, and RG2, the rat GBM tumor, were injected subcutaneously or intracerebrally with BP. The effects on tumor growth were determined by tumor volumes, magnetic resonance imaging and survival rate. Here, we report on the potency of BP in suppressing growth of malignant brain tumor cells without simultaneous fibroblast cytotocixity. BP up-regulated the expression of Cyclin Kinase Inhibitor (CKI), including p21 and p27, to decrease phosphorylation of Rb proteins, and down-regulated the cell-cycle regulators, resulting in cell arrest at the G(0)/G(1) phase for DBTRG-05MG and RG2 cells, respectively. The apoptosis-associated proteins were dramatically increased and activated by BP in DBTRG-05MG cells and RG2 cells, but RG2 cells did not express p53 protein. In vitro results showed that BP triggered both p53-dependent and independent pathways for apoptosis. In vivo, BP not only suppressed growth of subcutaneous rat and human brain tumors but also, reduced the volume of GBM tumors in situ, significantly prolonging survival rate. These in vitro and in vivo anti-cancer effects indicate that BP could serve as a new anti-brain tumor drug.
Mesh Headings (Keywords): Animals, Antineoplastic Agents, Apoptosis, Apoptosis Regulatory Proteins, Brain Neoplasms, Cell Cycle, Cell Cycle Proteins, Cell Line, Tumor, Cell Proliferation, Cyclin-Dependent Kinase Inhibitor p27, Drugs, Chinese Herbal, G0 Phase, Glioblastoma, Humans, Male, Mice, Mice, Transgenic, NIH 3T3 Cells, Phthalic Anhydrides, Rats, Survival Rate, Treatment Outcome
Check for Full Text / PubMed Unique Identifier (PMID): 16987298
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.